Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21609081 | 0.86 | CCKBR (0.42) | MEN1KMT2ASLC40A1 | |
| SCHEMBL21609231 | 0.84 | SLC40A1 (0.51) | MEN1KMT2ASLC40A1ATM | |
| SCHEMBL29652425 | 0.84 | ALDH1A1 (0.62) | MEN1KMT2ASLC40A1ALDH1A1MAPT | |
| SCHEMBL21609134 | 0.84 | ALDH1A1 (0.62) | MEN1KMT2ASLC40A1ALDH1A1MAPT | |
| SCHEMBL21609121 | 0.82 | EDNRA (0.50) | TYMSGAAALDH1A1MAPTTP53 | |
| SCHEMBL21609018 | 0.81 | KMT2A (0.52) | MEN1KMT2AGAAALDH1A1MAPT | |
| SCHEMBL21609028 | 0.80 | BRD4 (0.41) | MEN1KMT2ASLC40A1TP53CYP3A4 | |
| SCHEMBL21609022 | 0.80 | HTR2A (0.44) | — | |
| SCHEMBL21608956 | 0.79 | EDNRA (0.47) | KMT2ATP53 | |
| SCHEMBL29652562 | 0.79 | EDNRA (0.47) | KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | MEN1 122/4885KMT2A 4165/4885SLC40A1 459/4885 |
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | MEN1 121/4885KMT2A 4165/4885SLC40A1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.